Chevalet L, Tiraby G, Cabane B, Loison G
Sanofi Elf Bio Recherches, Unité de Microbiologie, Labège, France.
J Biotechnol. 1993 Feb;27(3):239-47. doi: 10.1016/0168-1656(93)90088-5.
Urate oxidase, an enzyme used in human therapy, is currently produced industrially by a strain of Aspergillus flavus. Two strategies of strain improvement were tested in order to obtain higher yields of urate oxidase. The first one, based on a classical mutation-selection protocol, led to the isolation of a mutant strain that overproduced uricase two-fold as compared to the industrial strain. The second one consisted in the construction of transformed strains that had integrated multiple copies of a urate oxidase-expression vector. A twenty-fold improvement in urate oxidase was obtained by this method.
尿酸氧化酶是一种用于人类治疗的酶,目前在工业上由一株黄曲霉生产。为了获得更高产量的尿酸氧化酶,测试了两种菌株改良策略。第一种基于经典的突变-选择方案,导致分离出一种突变菌株,与工业菌株相比,其尿酸酶产量高出两倍。第二种策略是构建整合了多个尿酸氧化酶表达载体拷贝的转化菌株。通过这种方法,尿酸氧化酶产量提高了20倍。